News and Events >

February 7, 2012 - Canaccord Genuity Musculoskeletal Conference, San Francisco

February 7 - 11, 2012 - American Academy of Orthopaedic Surgeons, San Francisco - Booth # 4753

February 10, 2012 - BioMimetic AAOS Paper Presentation, Moscone West, Room 2014 at 5:48 PM

March 1- 4, 2012 - American College of Foot and Ankle Surgeons, San Antonio - Booth 427

BioMimetic's Augment Bone Graft Receives Positive Recommendation from FDA Advisory Committee

GEM 21S Receives EU Approval

BioMimetic Therapeutics Receives Augment Bone Graft PMA Response Letter from FDA

Newly Published Augment Bone Graft Products Compare Favorably to Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion in Spine

BioMimetic Receives Approval of Augment Bone Graft in Australia

Newly Published rhPDGF-BB Pilot Data in Foot & Ankle International

New discoveries change everything.  How you see things.  How you change your approach.  Your own evolving technique then allows the magic, the breakthrough that challenges the ordinary.  That's why the surgeons who use BioMimetic's rhPDGF-BB orthobiologics are not satisfied with the status quo.  The Company’s lead product, Augment® Bone Graft, is designed to amplify the body’s natural healing process and eliminate the need for autograft, an invasive secondary surgical procedure requiring bone harvested from one part of the patient's body to be used in the primary surgical site, which often results in patient pain, morbidity, complications and increased operative time and blood loss.  Read more about our advances here, so you too, can reject ordinary.

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications.  All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration.  Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.

BioMimetic received regulatory approval in 2009 and 2011 to market Augment in Canada, and in Australia for hindfoot and ankle fusion indications.  Augment is pending regulatory decisions in the U.S. and European Union for similar indications.

GEM 21S is a trademark of Luitpold Pharmaceuticals, Inc., who now owns this dental related product and markets it through its Osteohealth division in the United States and Canada.

RECENT ANNOUNCEMENTS

BioMimetic Receives PMA Post Panel Response Letter
Jan. 3, 2012
 
GEM 21S EU Approval
Jan. 3, 2012
 
BioMimetic Therapeutics, Inc. Reports 2011 Third Quarter Earnings Results
Nov. 8, 2011
 
BioMimetic Therapeutics, Inc. Receives Approval to Commercialize Augment® Bone Graft in Australia
Oct. 19, 2011